How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors

NCT07268183 · tracked via the Priya Life Science France tracker

Sponsor

Hospices Civils de Lyon

Phase

Observational

Started

2026-01-06

Last updated

2026-01-22

Condition(s) studied

ProlactinomaMacroprolactinoma

Investigational drug(s) / intervention(s)

Standardized questionnaire

Standardized questionnaire: The intervention is a questionnaire which will be administered only if informations available on medical files are not sufficient. 1 mounth before questionning our cases and controls, they will receive a participant information note. It will be administered primarily by telephone. If the patient prefers not to answer by telephone, a paper version will be mailed to her. In this case, she will have up to two months to return the completed questionnaire by post. The questionnaire will collect detailed information on potential exposures to estrogens and reproductive history.

Study summary

Prolactinomas are the most common pituitary adenomas, representing about two-thirds of clinically relevant cases. Their prevalence is around 50 per 100,000 individuals, with an incidence of 3-5 new cases per 100,000 per year and has been rising in recent decades.

They may increase morbidity and mortality due to several factors:

* Hormone hypersecretion: excess prolactin causes galactorrhea, amenorrhea, and infertility.
* Mass effect: macroadenomas can compress adjacent structures, leading to headaches, visual loss, or neurological symptoms.
* Treatment complications: medical or surgical treatments may carry risks.

A marked sex difference exists, with a male-to-female ratio of 1:5-1:10, and peak diagnosis in women aged 25-44. This disparity disappears after menopause, supporting a potential role of estrogens in tumor development. Lactotrope cells, from which prolactinomas arise, are estrogen-sensitive, unlike other pituitary tumor cells (e.g., somatotrophs, gonadotrophs).

A large 2022 prospective cohort (nurses) suggested a possible association between pituitary adenomas and both combined oral contraceptives (COCs) and hormone therapy (HT). However, limitations included self-reported diagnoses, lack of adenoma characterization, and contradictory findings (association with HT but not consistently with COCs). A 2009 case-control study including all adenomas found no link with hormonal contraception, while older studies from the 1980s assessed high-dose contraceptives no longer in use.

Microprolactinomas are 4-5 times more frequent than macroprolactinomas (≥10 mm). Distinguishing between the two is essential, as they differ in clinical presentation, prognosis, and sex distribution. Macroadenomas are more common in men, possibly due to delayed diagnosis, as symptoms such as decreased libido are less specific, whereas women often present with amenorrhea or galactorrhea. However, studies suggest tumor size is not directly linked to symptom duration, indicating other factors may explain macroadenoma development.

Why some patients develop macro- rather than microadenomas remains unclear. Estrogen exposure is a possible explanation. It is therefore relevant to investigate whether women with macroprolactinomas had greater exposure to endogenous estrogens (early menarche, late menopause, pregnancies, breastfeeding) or exogenous estrogens (contraception, menopausal HT) compared to women with microprolactinomas.

The hypothesis is that women with macroprolactinomas were exposed to higher cumulative levels of estrogens before diagnosis than women with microprolactinomas.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria of cases : * Female patients aged ≥ 18 years at recruitment (diagnosis may have occurred before age 18). * Diagnosis of a prolactin-secreting macroadenoma established between January 2013 and December 2023. The diagnosis may have been made either in the Endocrinology Department of Hôpital Louis Pradel or by another medical team, whether within or outside the hospital setting. However, follow-up or part of the follow-up must have been performed in the Endocrinology Department of Hospices Civils de Lyon (HCL) * Diagnosis established by : A hypothalamic-pituitary MRI centered on the sella turcica, performed with gadolinium injection, including fine T1-weighted coronal and sagittal slices (1.5-3 mm), showing an adenoma with at least one axis measuring \> 10 mm, AND Serum prolactin \> 100 µg/L, or 24-100 µg/L with either a favorable response to medical therapy or histopathological confirmation after surgery. * Ability to understand the study and provide informed non-opposition. Inclusion Criteria of controls : * Female patients aged ≥ 18 years at the time of recruitment (diagnosis may have occurred before age 18). * Diagnosis of a prolactin-secreting microadenoma established between January 2013 and December 2023. The diagnosis may have been made in any medical center, but follow-up or part of the follow-up must have been carried out in the Endocrinology Department of Hôpital Louis Pradel. * Diagnosis must be based on: A hypothalamic-pituitary MRI centered on the sella turcica, performed with gadolinium injection, including fine T1-weighted coronal and sagittal slices (1.5-3 mm), showing a prolactin-secreting adenoma with all axes measuring \< 10 mm, AND A biological assessment performed outside any condition likely to bias results (significant stress, physical exertion, pregnancy, or intake of hyperprolactinemia-inducing drugs unrelated to prolactinoma treatment), showing serum prolactin \> 24 µg/L. * Ability to understand the nature and implications of the study and to provide informed non-opposition to participation. Exclusion Criteria of cases : * Presence of a non-secreting macroadenoma. * History of isolated hyperprolactinemia or an isolated pituitary lesion documented prior to 2013, without subsequent direct diagnosis of prolactinoma. * Presence of a known genetic abnormality or a genetic syndrome predisposing to the development of a prolactin-secreting adenoma. Exclusion Criteria of controls : * Presence of a non-secreting microadenoma. * Uncertain diagnosis of adenoma with an ongoing therapeutic trial. * Isolated hyperprolactinemia without evidence of adenoma. * Hyperprolactinemia or pituitary lesion without hyperprolactinemia documented prior to 2013, without subsequent direct diagnosis of prolactinoma. * Presence of a known genetic abnormality or a genetic syndrome predisposing to the development of a prolactin-secreting adenoma

Primary outcome measure(s)

number of patients exposed to combined estrogen-progestin contraception — week 4
Identify the estrogen-dependent risk factor
number of patients exposed to menopausal hormone therapy — week 4
Identify the estrogen-dependent risk factor
number of patients exposed to progestin-only treatment — week 4
Identify the estrogen-dependent risk factor
number of patients exposed to Ovarian Stimulation — week 4
Identify the estrogen-dependent risk factor
Age at First Use of Hormonal Contraception — week 4
Identify the estrogen-dependent risk factor
Age at Menarche — week 4
Identify the estrogen-dependent risk factor
Age at Menopause — week 4
Identify the estrogen-dependent risk factor
Age at First Live Birth — week 4
Identify the estrogen-dependent risk factor
Nulliparity — week 4
Identify the estrogen-dependent risk factor
Number of Pregnancies Carried to Viability — week 4
Identify the estrogen-dependent risk factor
Exposure to Breastfeeding defined as the total cumulative duration of breastfeeding across all pregnancies, expressed in months. • None: 0-1 month • Moderate: 1-12 months • High: >12 months — week 4
Identify the estrogen-dependent risk factor

Trial sites (1)

Facility	City	Region	Status
Hopital Louis Pradel	Bron	Rhone	Recruiting

More Hospices Civils de Lyon trials in France

Nosocomial Respiratory Virus Infection Recruiting

Retrospective and Prospective Cohort of Patients Entering the Multidisciplinary Management of Post-Covid Syndromes Recruiting

Blood Viscosity in Polycythemia Patients Recruiting

Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis Recruiting

Evaluation of the Efficacy and Acceptability of a Phytotherapy Combining Devil's Claw, Blackcurrant and Meadowsweet for the Management of Aromatase Inhibitor-induced Arthralgia in Patients Treated for Localized Breast Cancer in the Adjuvant Setting Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07268183 on ClinicalTrials.gov ↗ ← All trials in France